Compare Manhattan Associates Inc (MANH) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Pfizer Inc — how do they compare? Manhattan Associates Inc trades at $206.18 (market cap $11.79B), while Pfizer Inc trades at $27.83 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 13.5× Manhattan Associates Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manhattan Associates Inc for 12 Days and Pfizer Inc for 158 Days on average.
| MANH | PFE | |
|---|---|---|
Market Cap | $11.79B | $159.59B |
Volume | 393,599 | 30,937,010 |
Sector | Technology | Health |
52-Week High | $223.76 | $29.02 |
52-Week Low | $120.88 | $23.67 |
Typical Hold Time | 12 Days | 158 Days |
Enterprise Value | $11.66B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MANH trades at $202.11, down 0.36% on the day, with a bearish technical signal and key support at $201. The company shows strong profitability with a net income margin of 18.67% and has beaten earnings estimates for the last three quarters. Recent news includes a law firm investigation into fiduciary duties and a product launch of Editions for its supply chain solutions.
The outlook is mixed: strong fundamentals and analyst buy ratings support upside to the $210.50 consensus target, but technical weakness and the ongoing legal investigation pose near-term risks. Earnings growth remains the key catalyst for further price appreciation.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
